April 2019 in “Journal of the Endocrine Society” Androgens and estrogens are crucial for insulin secretion in males.
February 2019 in “Journal of Physiology & Pathology in Korean Medicine” Puerariae Radix extract may be a promising cosmetic ingredient for skin health.
January 2019 in “ISGE series” Estrogen helps prevent artery plaque by stopping monocyte capture in blood vessels.
September 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Prostaglandin D2 increases testosterone production in skin cells through a process involving reactive oxygen species, which could be a new target for treating hair loss and other skin conditions driven by testosterone.
April 2016 in “Journal of Investigative Dermatology” Autophagy, a cell recycling process, is crucial for prolonged hair growth and could be a potential target for treating hair growth disorders.
Pygo2 is important for early growth and progression of intestinal tumors, and could be a target for treating cancers with certain mutations.
April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.
P-3074 effectively blocks scalp DHT better than oral finasteride.
March 2013 in “Pigment Cell & Melanoma Research” A gene called Taqpep affects cat coat patterns like stripes and blotches.
April 2010 in “The Journal of Urology” The research found that androgens help control blood flow in the rat prostate through a specific binding site.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
June 2008 in “Alcoholism Clinical and Experimental Research” Certain drugs can block changes in brain receptors caused by alcohol withdrawal.
January 2007 in “Edward Elgar eBooks” TSPO might help treat anxiety and depression.
Potassium channel openers like minoxidil boost hair growth.
November 2003 in “Journal of Neurochemistry” Allopregnanolone may enhance alcohol's effects on dopamine neurons, influencing addiction risk.
41 citations
,
December 2008 in “Current Opinion in Ophthalmology” Certain eye surgery complications can be managed effectively, especially in patients who have used specific prostate medications.
31 citations
,
April 2019 in “Experimental and Therapeutic Medicine” β-blockers can cause skin problems like psoriasis and vitiligo, and doctors should tell patients about these risks.
28 citations
,
March 2013 in “Journal of Investigative Dermatology” Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.
27 citations
,
August 1999 in “Urology” Finasteride improves urinary function in men for 2 years.
26 citations
,
June 1983 in “Journal of Hypertension” Minoxidil lowers blood pressure more effectively but has more side effects, so try hydralazine first.
22 citations
,
April 1985 in “Australasian Journal of Dermatology” Beta-blockers can cause rare skin side-effects, which usually improve after stopping the medication.
19 citations
,
June 2013 in “Journal of Neuroendocrinology” Neurosteroids may help prevent seizures and slow epilepsy progression.
16 citations
,
March 1981 in “PubMed” Minoxidil significantly lowers blood pressure in patients with hard-to-treat hypertension, but can cause fluid retention and excessive hair growth.
12 citations
,
January 1998 in “Drug safety” Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.
4 citations
,
September 2002 in “Der Urologe” Combination therapy is more effective for prostate volumes over 60 ml.
1 citations
,
May 2017 in “Urologe A” Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.
1 citations
,
April 2012 in “Urology” Self-management can help improve symptoms of benign prostatic hyperplasia.
May 2026 in “SKIN The Journal of Cutaneous Medicine” Bimekizumab can improve scarring alopecia in severe psoriasis.
February 2026 in “Postgraduate Medicine” 5-alpha reductase inhibitors slightly increase depression risk, but the risk varies based on the control group used.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.